Indoleamine-Pyrrole 2,3,-Dioxygenase
"Indoleamine-Pyrrole 2,3,-Dioxygenase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A dioxygenase with specificity for the oxidation of the indoleamine ring of TRYPTOPHAN. It is an extrahepatic enzyme that plays a role in metabolism as the first and rate limiting enzyme in the kynurenine pathway of TRYPTOPHAN catabolism.
| Descriptor ID |
D050503
|
| MeSH Number(s) |
D08.811.682.690.416.333
|
| Concept/Terms |
Indoleamine-Pyrrole 2,3,-Dioxygenase- Indoleamine-Pyrrole 2,3,-Dioxygenase
- Indolamine-2,3-Dioxygenase
- Indolamine 2,3 Dioxygenase
- Indoleamine-Oxygen 2,3-Oxidoreductase (Decyclizing)
- IDO Dioxygenase
- Dioxygenase, IDO
- Indoleamine 2,3-Dioxygenase
- Indoleamine 2,3 Dioxygenase
|
Below are MeSH descriptors whose meaning is more general than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
Below are MeSH descriptors whose meaning is more specific than "Indoleamine-Pyrrole 2,3,-Dioxygenase".
This graph shows the total number of publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in this website by year, and whether "Indoleamine-Pyrrole 2,3,-Dioxygenase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 2 | 1 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 4 | 1 | 5 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 1 | 4 |
| 2021 | 2 | 2 | 4 |
| 2022 | 2 | 3 | 5 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 2 | 2 |
| 2025 | 1 | 0 | 1 |
| 2026 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indoleamine-Pyrrole 2,3,-Dioxygenase" by people in Profiles.
-
Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205. Clin Cancer Res. 2026 Aug 14; 32(16):3476-3492.
-
Therapeutic remodeling of the tuberculosis granuloma with 1-methyl-D-tryptophan enhances CD8+ T cell-macrophage interactions. Proc Natl Acad Sci U S A. 2026 08 18; 123(33):e2528104123.
-
Circulating PEG-indoleamine 2,3-dioxygenase ameliorates diverse inflammatory diseases without toxicity or compromising immunocompetence. Proc Natl Acad Sci U S A. 2026 Jul 14; 123(28):e2602536123.
-
Injectable hydrogel-based localized delivery of IDO-galectin-3 mitigates neuroinflammation and promotes neuronal sparing after spinal cord contusion in rats. J Mater Chem B. 2026 Mar 18; 14(11):3464-3479.
-
A single intra-articular injection of IDO-Gal3 shifts synovial fluid metabolic profiles for up to six weeks in male rats with knee instability. Biochimie. 2026 Sep; 248:107-120.
-
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC). J Med Chem. 2025 Feb 27; 68(4):4961-4987.
-
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer. 2024 Jul 25; 23(Suppl 1):1250.
-
Human cytomegalovirus in breast milk is associated with milk composition and the infant gut microbiome and growth. Nat Commun. 2024 07 23; 15(1):6216.
-
Intra-articular delivery of an indoleamine 2,3-dioxygenase galectin-3 fusion protein for osteoarthritis treatment in male Lewis rats. Arthritis Res Ther. 2023 09 18; 25(1):173.
-
Suppression of local inflammation via galectin-anchored indoleamine 2,3-dioxygenase. Nat Biomed Eng. 2023 09; 7(9):1156-1169.